← Leaderboards
Lynda A. Morrison
Saint Louis University
$4,216,403
Attributed
$4,931,251
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $611.6K · FY2005–19$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$4,931,251 · 12
By mechanism
R21$2,406,374 · 6
R01$1,455,145 · 1
R41$448,895 · 2
R29$324,064 · 1
R03$296,773 · 2
Top collaborators
- David J Davido4 shared
- Stuart John Macdonald2 shared
- Bruce Lee Rogers2 shared
Others in their field
Top investigators on “Simplexvirus”
- David Leung · National Jewish Health$31,859,607
- Daniel F. Hoft · Saint Louis University$26,271,892
- Thomas Denny · Duke University$23,095,705
- Anna Wald · University Of Washington$22,896,580
- Homayon Ghiasi · Cedars-Sinai Medical Center$19,611,810
- David M Knipe · Harvard Medical School$18,668,685
Research focus
SimplexvirusVirusMutantInfectionGenital SystemViralLesionVirionResponseAntiviral AgentsVirus ReplicationHerpesvirus 1, HumanCorneaVirulenceRecurrenceMediatingHuman Herpesvirus 2ProteinsPreventIn VivoPlayHerpesvirus 1Mouse ModelMutation
Grant awards (26)
Nucleotidyl transferase antagonists as inhibitors of HSV replication$227,250
R21 · FY2019 · AI · contact PI
Developing novel combination therapies for HSV genital infection.$223,895
R41 · FY2018 · AI
Nucleotidyl transferase antagonists as inhibitors of HSV replication$189,375
R21 · FY2018 · AI · contact PI
Dissecting the Contribution of Viral Genetic Variation to HSV-1 Neuropathogenesis$226,223
R21 · FY2017 · NS · contact PI
Hit-to-Lead optimization of small-molecule inhibitors of herpes simplex viruses$225,000
R41 · FY2017 · AI
Dissecting the Contribution of Viral Genetic Variation to HSV-1 Neuropathogenesis$201,337
R21 · FY2016 · NS · contact PI
Frequency and pattern of resistance mutations to novel inhibitors of HSV-1$75,750
R03 · FY2016 · AI · contact PI
Frequency and pattern of resistance mutations to novel inhibitors of HSV-1$75,750
R03 · FY2015 · AI · contact PI
Virus-encoded costimulation molecules to improve HSV-2 vaccine efficacy$219,038
R21 · FY2011 · AI · contact PI
An antiviral function of cellular PrP identified using HSV-1 ICP34.5 mutant virus$178,286
R21 · FY2011 · AI · contact PI
An antiviral function of cellular PrP identified using HSV-1 ICP34.5 mutant virus$217,887
R21 · FY2010 · AI · contact PI
Improving Vaccine Safety and Efficacy to Control Primary HSV-1 Infections$209,309
R21 · FY2010 · EY · contact PI
Virus-encoded costimulation molecules to improve HSV-2 vaccine efficacy$184,375
R21 · FY2010 · AI · contact PI
Improving Vaccine Safety and Efficacy to Control Primary HSV-1 Infections$201,413
R21 · FY2009 · EY · contact PI
Functional analysis of HSV-2 tegument proteins in mice$273,469
R01 · FY2008 · AI · contact PI
Functional analysis of HSV-2 tegument proteins in mice$278,765
R01 · FY2007 · AI · contact PI
Functional analysis of HSV-2 tegument proteins in mice$287,091
R01 · FY2006 · AI · contact PI
Vaccine to Prevent HSV-induced keratitis$185,622
R21 · FY2006 · EY · contact PI
Substrate recognition motif of the HSV-2 UL 13 kinase$71,773
R03 · FY2006 · AI · contact PI
Functional analysis of HSV-2 tegument proteins in mice$294,000
R01 · FY2005 · AI
Vaccine to Prevent HSV-induced keratitis$166,259
R21 · FY2005 · EY
Substrate recognition motif of the HSV-2 UL 13 kinase$73,500
R03 · FY2005 · AI
Functional analysis of HSV-2 tegument proteins in mice$321,820
R01 · FY2004 · AI
MECHANISMS OF MUCOSAL IMMUNITY TO HERPES SIMPLEX VIRUS$115,083
R29 · FY2002 · CA
MECHANISMS OF MUCOSAL IMMUNITY TO HERPES SIMPLEX VIRUS$107,256
R29 · FY2001 · CA
MECHANISMS OF MUCOSAL IMMUNITY TO HERPES SIMPLEX VIRUS$101,725
R29 · FY2000 · CA